-

IPA to Present at Jefferies Healthcare Conference 2023

VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx. The replay of the webcast will be available for 90 days.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com.

Contacts

Investor: investors@ipatherapeutics.com

Industry:

ImmunoPrecise Antibodies

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$XBI
Hashtags
#AI
#BioStrand
#Omics
#antibodydiscovery
#bioinformatics
#biotechnology
#biotherapeutics
#covid19
#drugdiscovery
#futurepandemic
#omics
#personalizedmedicine
#polytope
#precisionmedicine
#variants

Contacts

Investor: investors@ipatherapeutics.com

Social Media Profiles
Facebook
Linkedin
Substack
Twitter
YouTube
More News From ImmunoPrecise Antibodies

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today outlined why the ontology layer now being built across enterprise AI does not reach biological function, and why life sciences requires a biological context layer of its own. ReefIQ™, MindWalk's biological context layer for life sciences, supplies what a horizontal ontology cannot: a governed, model-agnostic representation of what biology does, available from the first day of a de...

MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced the appointment of Kim Remizowski to its Board of Directors as an independent director, effective September 29, 2026. Mr. Remizowski will serve on the Audit Committee and the Compensation, Nomination and Governance Committee. The Board has determined that he qualifies as an independent director under Nasdaq listing rules and as an audit committee financial expert under a...

MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced results from a production deployment of the open-source OpenFold3 structure prediction model, run with engineering partners AMD and Vultr on Vultr Kubernetes Engine and Vultr Cloud GPU powered by AMD Instinct™ MI325X GPUs and delivered through AMD Inference Microservices (AIM). It also served as an independent validation of AIM for OpenFold3 in a production life-sciences...
Back to Newsroom